A Phase III Study to Compare Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan 200 Mg/m(2) and Autologous Transplantation (MEL200) In Newly Diagnosed Multiple Myeloma Patients

Palumbo Antonio; Cavallo Federica; Hardan Izhar; Ciccone Giovannino; Larocca Alessandra; Cavalli Maide; Peccatori Jacopo; Carella Angelo Michele; Brioli Annamaria; Cafro Anna Maria; Patriarca Francesca; Siniscalchi Agostina; Pezzatti Sara; Crippa Claudia; Montefusco Vittorio; Levi Anna; Ruggeri Marina; Caravita Tommaso; Ben Yehuda Dina; Di Raimondo Francesco; Boccadoro Mario

赞收藏引用

科研之友

微信

新浪微博

Facebook

分享链接

A Phase III Study to Compare Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan 200 Mg/m(2) and Autologous Transplantation (MEL200) In Newly Diagnosed Multiple Myeloma Patients

作者：Palumbo Antonio; Cavallo Federica; Hardan Izhar; Ciccone Giovannino; Larocca Alessandra; Cavalli Maide; Peccatori Jacopo; Carella Angelo Michele; Brioli Annamaria; Cafro Anna Maria; Patriarca Francesca; Siniscalchi Agostina; Pezzatti Sara; Crippa Claudia; Montefusco Vittorio; Levi Anna; Ruggeri Marina; Caravita Tommaso; Ben Yehuda Dina; Di Raimondo Francesco; Boccadoro Mario

来源：52nd Annual Meeting of the American-Society-of-Hematology (ASH), 2010-12-04 to 2010-12-07.

出版日期2010-11-19

收藏分享被引(1) 浏览

更新时间：2018-02-09 19:01

相似论文
引用论文
参考文献

A Phase III Study to Compare Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan 200 Mg/m(2) and Autologous Transplantation (MEL200) In Newly Diagnosed Multiple Myeloma Patients

产品服务

站内浏览

服务支持

联系方式

科研之友